Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting
Ernexa Therapeutics (Nasdaq: ERNA) will present preclinical data from its iPSC-derived iMSC platform in an oral presentation at the 67th ASH Annual Meeting in Orlando, Dec 6-9, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ernexa Therapeutics (Nasdaq: ERNA) will present preclinical data from its iPSC-derived iMSC platform in an oral presentation at the 67th ASH Annual Meeting in Orlando, Dec 6-9, 2025. The talk, titled "Gene-modified iPSC-derived MSCs convert immunosuppressive tumor microenvironments into distinct Pro-inflammatory TMEs," (abs25-15026) is scheduled for Dec 6, 2025, 3:00–3:15 PM EST in Chapin Theater (320).
The presentation covers preclinical findings supporting ERNA-101, Ernexa's lead ovarian cancer candidate and its approach to reprogram TMEs to stimulate T-cell anti-tumor activity.
Details
News Market Reaction – ERNA
On Dec 3, the day this news came out, ERNA closed 4.17% below the previous close.
Data tracked by StockTitan Argus for the Dec 3 session.
Key Figures
- ASH Annual Meeting dates
- December 6–9, 2025
- 67th ASH Annual Meeting in Orlando
- Oral presentation time
- 3:00–3:15 PM EST
- ASH oral session on December 6, 2025
- Session number
- 703
- Cellular Immunotherapies other than CAR-T Cells session
- Q3 2025 net loss
- $1.24 million
- Quarter ended September 30, 2025
- Prior-year Q3 net loss
- $26.60 million
- Quarter ended September 30, 2024
- Cash balance
- $3.05 million
- As of September 30, 2025 (10-Q filing)
- Operating loss decline
- 44%
- Nine months ended Sept 30, 2025 vs prior year
- Preclinical survival advantage
- 58.2%
- ERNA-101 in preclinical ovarian cancer model
Historical Context
-
Preclinical ERNA-101 data showing TME reprogramming and survival benefit.
-
Announcement of ASH oral talk on iPSC-derived MSC platform for ERNA-101.
-
Addition of leading gynecologic oncologist to advisory board for ERNA-101.
-
Presentations at Cell 2025 on iMSC platform development and strategy.
-
Report of lower operating loss and ERNA-101 preclinical survival advantage.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
induced pluripotent stem cells medical
induced mesenchymal stem cells medical
tumor microenvironments medical
pro-inflammatory cytokines medical
t cells medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that data from its novel cell therapy platform will be shared in an oral presentation at the 67th ASH Annual Meeting, being held December 6-9, 2025 in Orlando, FL.
“Being selected to give an oral presentation at ASH is a tremendous honor and a major milestone,” said Sanjeev Luther, President & CEO of Ernexa Therapeutics. “It’s a recognition of the potential of our iMSC platform to transform the tumor microenvironment and drive a targeted immune response. We’re proud to share this work and move closer to delivering innovative therapies for patients facing ovarian cancer and other hard-to-treat diseases.”
Details of the oral presentation are as follows:
Title: Gene-modified iPSC-derived MSCs convert immunosuppressive tumor microenvironments (TMEs) into distinct Pro-inflammatory TMEs
Abstract Number: abs25-15026
Presenter: Michael Andreeff, MD, PhD, Professor of Medicine, Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center
Session: 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Cellular Immunotherapy Beyond CAR-T: Emerging Platforms and Strategies
Presentation Date and Time: December 6, 2025 from 3:00 PM - 3:15 PM EST
Location: OCCC - Chapin Theater (320)
The data being presented reflects preclinical findings supporting ERNA-101, Ernexa’s lead therapy candidate for ovarian cancer. This oral presentation will highlight Ernexa’s unique approach of using gene-modified induced pluripotent stem cells (iPSCs) that are engineered into induced mesenchymal stem cells (iMSCs) to overcome tumors’ natural defenses. By harnessing iMSCs’ ability to home to tumors and engineering them to release pro-inflammatory cytokines, our platform is designed to turn immunosuppressive tumor environments into ones that activate the immune system, helping T cells attack cancer more effectively.
About Ernexa Therapeutics
Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.
ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.
For more information, visit www.ernexatx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Ernexa's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa's risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.
Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com
Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ENRA@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.